Address correspondence to Mark Bix, Dept. of Immunology, University of Washington, 1959 N.E. Pacific St., HSC I607I, Seattle, WA 98195. Phone: (206) 543-6633; Fax: (206) 221-5433; email: mbix{at}u.washington.edu
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key Words: early IL-4 naive T cell BALB/C Dice IL-4
Abbreviations used in this paper: QTL, quantitative trait locus/loci; SSLP, simple sequence length polymorphism.
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
IL-4, the signature cytokine of Th2 cells, is itself a critical determinant of Th2 cell development (4). On naive CD4 T cells (the common progenitor of Th1 and Th2 cells), IL-4 engages the IL-4R to activate STAT6 that in turn up-regulates the zinc finger transcription factor GATA3, a master regulator of Th2 cell development (5, 6). The initial in vivo source of the IL-4 necessary to instruct Th2 cell development has been controversial, with reports of contributions from mast cells, basophils, eosinophils, and NK T cells (7, 8). Although it is difficult to exclude that in specific contexts each of these cell types may play instructive roles for Th2 cell development, it is clear that in the absence of inflammatory stimuli such as IL-12 and IFN-, naive Th cells can suffice to instruct their own Th2 cell development by an autocrine IL-4 pathway (911). The initial production of IL-4 in this pathway occurs even in the presence of blocking antiIL-4R antibody or from STAT6 KO naive Th cells. Despite its critical role in the initiation of Th2 cell development, the TCR-dependent, IL-4R/STAT6-independent pathway regulating the production of IL-4 from naive Th cells is not well understood.
The ability of naive Th cells to express IL-4 rapidly (hereafter, nIL-4) and Th2 cell bias are linked phenotypic traits subject to a wide degree of genetic variation. Among common inbred mouse strains, these traits range from the high nIL-4/high Th2 cell bias phenotypes of BALB/c to the low nIL-4/low Th2 cell bias phenotypes of C57BL/6 and B10.D2 (911). Susceptibility to L. major infection correlates with the high nIL-4/high Th2 cell bias phenotypes of BALB/c, consistent with the known antagonistic role of Th2 cell responses in the IFN-dependent activation of macrophages required by the host to control intracellular parasite replication (12, 13).
To gain a better understanding of the genetic determinants controlling susceptibility to Th2 celldependent diseases, we earlier performed linkage analysis on a [(BALB/c x C57BL/6)F1 x C57BL/6] backcross cohort to identify loci regulating Th2 cell bias (9). 63 mice were genotyped for the segregation of simple sequence length polymorphism (SSLP) markers distributed across the genome at an average density of 10 cM. These data were correlated with phenotypic measurements of Th2 cell bias by determining the quantitative level of IL-4 secreted into the media of CD4-enriched splenocyte cultures activated by TCR ligation. In this culture system, parental BALB/c cells secrete 50-fold more IL-4 than C57BL/6 or B10.D2, and F1 animals display an intermediate phenotype, demonstrating codominant inheritance of this trait (9). The phenotype distribution profile of the backcross cohort indicated that Th2 cell bias was a multigenic trait (9). A quantitative trait locus (QTL) designated Dice1, accounting for 27% of the trait variance, was detected on centromeric chromosome 16 (9).
Here, we describe the use of interval-specific congenic mapping to identify the Th2 cell bias-controlling locus predicted by the Dice1 QTL. Instead of one, we discovered two loci, Dice1.1 and Dice1.2, which control Th2 cell bias. In each case, the proximal target of this genetic control is likely to be in the nIL-4 pathway, as both loci also control nIL-4 levels. Despite sharing in common the ability to control nIL-4 and Th2 cell bias, we found that only one locus (Dice1.2) could control susceptibility to L. major infection. We discuss the implications of these findings for the role of Th2 cell bias in determining L. major susceptibility.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Producing Recombinant Congenic Strains.
BALB.D2c16 was backcrossed to BALB/cAnN and progeny were screened for recombination across the congenic interval using SSLP markers spanning chromosome 16 (see Online Supplemental Material section below for marker information). Nine animals were selected that together harbored a set of recombinant congenic intervals (19) comprising a tiling path across most of chromosome 16. Each of these was then backcrossed to BALB/cAnN. Nonrecombinant progeny from each backcross were identified by SSLP screening and intercrossed to produce homozygous recombinant congenic animals. These were identified by SSLP screening and then intercrossed to generate a pure-breeding stock that had been backcrossed to BALB/cAnN at least 11 times. The nine congenic lines are designated C.16D2/1, C.16D2/2, C.16D2/3, C.16D2/4, C.16D2/5, C.16D2/6, C.16D2/7, C.16D2/8, and C.16D2/9.
Th2 Cell Bias Assay.
CD4-enriched splenocytes were prepared by complement-mediated lysis of CD8+ T cells (3.155; American Type Culture Collection [ATCC]]), MHC class II+ B cells, dendritic cells, and macrophages (BP107; ATCC), and HSA+ B cells, + T cells, monocytes, granulocytes, and erythrocytes (J11d; ATCC). CD4 T cell purity, as determined by FACS analysis, was always >80%. In brief, total splenocytes (30 x 106/ml) were incubated at 37°C in a cocktail of purified antibodies and a combination of rabbit and guinea pig complement for 50 min. Live cells were recovered by centrifugation through Ficoll, washed, resuspended in cell culture medium (RPMI 1640 with 10% heat-inactivated fetal calf serum, 50 µM ß-mercaptoethanol, 2 mM L-glutamine, and 100 U/ml penicillin and streptomycin), counted, and distributed (106 CD4 T cell equivalents/well, determined by FACS analysis) with 25 U/ml recombinant human IL-2 (Roche) into 24-well plates precoated with 1 ug/ml anti-TCRßspecific antibody (H57.597; ATCC). On day 5, cells were harvested, washed extensively, counted, and redistributed (105/well) with 25 U/ml recombinant human IL-2 (Roche) into 96-well, flat-bottom plates precoated with 10 ug/ml anti-TCRßspecific antibody (H57.597; ATCC). 2 d later, supernatants were harvested and IL-4 content was determined by ELISA (coating antibody, 11B11 [NIH Response modifier program]; detecting antibody, BVD6 [ATCC]).
nIL-4 Assay.
Total RNA was isolated (STAT60; Tel-Test) from CD4-enriched splenocytes (prepared and cultured as described above) after 16 h of stimulation. RNA was converted to cDNA with reverse transcriptase (Superscript II; Invitrogen) according to the manufacturer's instructions. Il4 and Hprt sequence content was then measured by quantitative real-time PCR using intron-spanning primers (Il4: 5'-CTTATCGATGAATCCAGGCATCG-3' and 5'-CATCGGCATTTTGAACGAGGTCA-3'; Hprt: 5'-GAGGGTAGGCTGGCCTATAGGCT-3' and 5'-GTTGGATACAGGCCAGACTTTGTTG-3'). Il4 expression was normalized internally to Hprt. These normalized values were then expressed relative to expression in NIH3T3 fibroblasts (ATCC) that do not express Il4 (unpublished data).
L. major Infection.
Cohorts of anesthetized mice were inoculated in both hind footpads with 4 x 105 metacyclic promastigotes of L. major (strain WHOM/IR/-/173), maintained as described previously (14). The size of footpad lesions was monitored weekly using metric calipers. Footpad thickness measurements are presented as the value measured on a given day (the group mean of six replicate measurements: three/foot/animal) minus the value measured just before infection. 56 wk after infection, animals were killed and footpad parasite burdens were determined. Footpads were washed in ethanol and rinsed and homogenized in 10 ml M199 media using a Tissu-Tearor (model 398; Biospec Products). Homogenates were serially diluted into 96-well microtiter plates and incubated in the dark at room temperature for 1 wk. Wells were monitored daily for motile promastigotes using inverted microscopy.
Statistical Analysis.
To compare results from different strains and from different experiments conducted over a period of time, we converted raw measurements into Index values (Itest) that normalized each mouse to the BALB/c and B10.D2 controls in a given experiment. This was computed as follows: Itest = (test meanB10.D2)/(meanBALB/c meanB10.D2). In this way, Itest values approaching 1 correspond to a BALB/c-like phenotype and those approaching 0 indicate a B10.D2-like phenotype. Before performing individual comparison tests of statistical significance, the statistical significance of each entire dataset was first assessed using the nonparametric Kruskal-Wallis test (nIL-4: P < 0.0001; Th2 cell bias: P < 0.0001). Multiple comparisons between control BALB/c and each C.16D2 congenic strain were then assessed using the nonparametric Mann Whitney test. Results of this analysis are shown in the legend to Fig. 3.
Online Supplemental Material
Table S1 shows SSLP markers used to map chromosome 16. Shown are their names, positions on chromosome 16 (NCBI Mapviewer, build 33.1), forward and reverse primer sequences, and respective BALB/c and B10.D2 amplicon sizes (in basepairs). D16MIT markers are from MIT/Whitehead, whereas DA1.5, D1.3, D8.3, and D10.2 were generated by us. Table S1 is available at http://www.jem.org/cgi/content/full/jem.20040334/DC1.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
|
L. major Susceptibility of C.16D2 Congenic Strains.
Given the known role that Th2 cell bias plays in the susceptibility of the BALB/c strain to infection by the protozoal parasite L. major (1), we hypothesized that the Dice1.1+ and Dice1.2+ C16.D2 strains would display reduced susceptibility compared with BALB/c. To test this, we injected parasites into the footpads of control and congenic mice and followed the infection course by measuring footpad thickness at weekly intervals and footpad parasite burdens at the end of the assay. Contrary to our expectation, the Dice1.1+ C.16D2/3 and C.16D2/5 strains shared an infection course with the susceptible Dice1.1 C.16D2/6 strain and the BALB/c control (Fig. 4, A and C). By contrast, the Dice1.2+ C.16D2/8 strain exhibited an infection course shifted toward the resistant phenotype of the B10.D2 control (Fig. 4 C). The susceptible and resistant phenotypes of mice harboring Dice1.1 and Dice1.2 congenic intervals, respectively, was also reflected in footpad parasite burdens (Fig. 4, B and D). Thus, the Dice1.2 but not the Dice1.1 congenic interval contains an L. major response locus.
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
To confirm and genetically resolve the Dice1 QTL controlling Th2 cell bias, a trait associated with susceptibility to allergic airway disease and L. major infection, we undertook the classical interval-specific congenic mapping approach of Snell and Bunker (15). This approach converts a complex multigenic trait into its component genes, each isolated on distinct congenic intervals, segregating in separate inbred strains that, once produced, are good substrates for straightforward positional, expression, and/or candidate gene cloning strategies. The main pitfall of the approach is that phenotypic expression of a targeted QTL, once isolated from other genes contributing to the measured trait, may no longer be sufficiently strong and penetrant to allow reliable detection. Second, even if scorable phenotypes are maintained, there is no guarantee that a particular QTL will contain only a single gene. Indeed, it is not uncommon (as was the case in this study) for QTL to resolve into multiple distinct loci (17). In this case, further genetic resolution will depend upon each component gene's ability to confer continued phenotypic detection. Fortunately, this dilution effect can be offset partially in the case of recessive and codominantly inherited traits by interrogating congenic intervals in their homozygous state. Despite its potential shortcomings, interval-specific congenic mapping is proving to be a powerful tool for the identification of component genes involved in complex multigenic traits. Prominent recent examples include susceptibility to allergic airway disease (asthma) and autoimmune disease (systemic lupus erythematosus; references 12 and 19). This study adds Dice1 to the growing list of QTL that have yielded to interval-specific congenic mapping, an example, in this case, of a locus controlling susceptibility in an experimental model of a human infectious disease, cutaneous leishmaniasis.
The Th2 cell bias phenotypes conferred by Dice1.1 and Dice1.2 were both incompletely penetrant, requiring the analysis of multiple mice for their reliable detection. This result is consistent with the expectation that each component gene involved in a multigenic trait will contribute only a portion of the overall phenotype. It will be interesting to compare the phenotypes of bicongenic mice harboring both Dice1.1 and Dice1.2 with either monocongenic. An additive/non-epistatic phenotype would suggest that Dice1.1 and Dice1.2 participate in parallel pathways, whereas a synergistic or epistatic phenotype would suggest participation in a linear pathway. Given that the original Dice1 QTL could only account for 27% of the variance in Th2 cell bias between BALB/c and C57BL/6 in our original backcross cohort, it is perhaps surprising that the phenotypes controlled by Dice1.1 and Dice1.2 are so robust. Most likely, this reflects the advantage of scoring a codominant trait within animals harboring homozygous congenic B10.D2 intervals on a genetically homogeneous BALB/c background in the absence of confounding epistatic "noise" present in the original backcross cohort, resulting from the random segregation of multiple interacting B10.D2 intervals.
Identifying Genes Involved in Th2 Celldependent Diseases by Screening Genetic Loci Involved in Th2 Cell Bias.
Susceptibility to many immunological diseases arises from variation in the type of Th cell response elicited by foreign agents. In particular, susceptibility to allergic airway disease and cutaneous leishmaniasis is associated with inappropriate Th2 cellbiased responses (1, 12, 13). We hypothesized that disease susceptibility genes could be identified by focusing on simpler cellular (as opposed to organismal) traits that control key disease susceptibility pathways. Thus, we set out to identify genes involved in controlling Th2 cell bias with the hope that these would lead to the identification of genes involved in Th2 celldependent diseases. Providing validation for this approach, a recent study of asthma susceptibility exploited the HBA congenic strain, produced on a BALB/c background with a chromosome 11 genomic interval inherited from DBA/2. Although the congenic interval in this strain was selected on the basis of its ability to regulate Th2 cell bias, subsequent positional cloning uncovered the controlling Tim gene family as having a role in asthma susceptibility (20). Similarly, our interval-specific congenic mapping of the Th2 cell bias regulatory Dice1 QTL led to identification of a novel response locus for L. major. Together, these two examples support the general strategy of identifying genes involved in genetically complex Th2 celldependent susceptibility phenotypes by screening loci involved in controlling a simpler cellular phenotype: Th2 cell bias. It remains to be seen whether the Tim gene family plays a role in L. major susceptibility or if Dice1.1 and Dice1.2 play a role in asthma susceptibility.
Candidate Genes.
The minimal Dice1.1 congenic interval spans 3.2 Mb, contains 35 genes (NCBI Mapviewer, build 33.1), and overlaps the 95% confidence interval for the location of the original Dice1 QTL (2.5 cM centered on D16MIT81; reference 9). Potential candidate genes in this interval include those encoding transcription factors CRHSP-24 and CIITA and the intracellular signaling protein SOCS1 (2123). Of these, the transcription factor CIITA is perhaps the most interesting insofar as it has been shown to interfere directly with Il4 expression in vivo (22). However, despite significantly lower expression of Il4 in 16-h stimulated splenocytes from C57BL/6 compared with BALB/c, no difference was detected in the level of C2ta mRNA (unpublished data). We cannot exclude the possibilities that analysis of highly purified naive CD4 T cells would reveal differential expression for C2ta or that a structural polymorphism underlies Dice1.1. Comparative sequencing and further differential expression analysis studies of C2ta and other Dice1.1 candidate genes are ongoing.
The minimal Dice1.2 congenic interval is large, spans 27.6 Mb, and includes 145 genes (NCBI Mapviewer, build 33.1). Potential candidate genes in this interval include those encoding the HMG box transcription factor BBX, the E3 ubiquitin ligase CBL-B, and the pituitary-specific transcription factor PIT1 (2426). Another Th2 cell bias-controlling QTL called Cypr1 (cytokine production 1) has been mapped to a region of chromosome 16 just centromeric of the Dice1.2 interval (27), suggesting the possible identity of the locus predicted by Cypr1 and Dice1.2. The founding mouse used to produce the C.16D2 panel arose in the course of a study that used serial backcross mapping to identify six L. major resistance QTL, one of which mapped to the distal part of chromosome 16 (16). Transmission/disequilibrium testing suggested that this QTL was dependent upon epistatic interactions for its phenotypic expression, possibly explaining why its association with resistance in that study fell short of statistical significance. Nonetheless, one of the two chromosome 16 SSLP markers (D16MIT5) with the lowest p-values for association with resistance in this earlier study occurs within the Dice1.2 congenic interval, suggesting the possibility of identity between the locus predicted by this QTL and the L. major response locus we have identified.
The Functions of Dice1.1 and Dice1.2.
The strength of the nIL-4 and Th2 cell bias phenotypes (as reflected in the magnitude of Mann-Whitney p-values) displayed excellent concordance in all nine C16.D2 strains. The strength of both phenotypes was uniformly higher for strains containing Dice1.1 as opposed to Dice1.2. Together with the known requirement for nIL-4 in the development of Th2 cell bias (911), this result strongly suggests that the primary targets of both Dice1.1 and Dice1.2 are in the nIL-4 pathway. Developmental acquisition of the Dice-controlled nIL-4 trait has been shown to be T cell lineage autonomous (9), implying that Dice1.1 and Dice1.2 also act directly within naive T cells rather than indirectly through some other interacting cell type. Previous studies have shown that the Th2 cell bias trait is reflected in the proportion of IL-4expressing cells as opposed to the level of IL-4 expression per cell, indicating a stochastic element to the Th2 cell commitment process (9). Together, our evidence that Dice1.1 and Dice1.2 influence Th2 cell bias indirectly through effects on nIL-4 imply that the level of IL-4 secreted by naive CD4 T cells contributes to their likelihood of maintaining Il4 in a transcriptionally permissive state. Biochemical and proteomic analysis of Th cells from the C.16D2 congenic strains will allow elucidation of the signaling pathways and components proximal to the Dice1.1 and Dice1.2 gene products, and may facilitate the identification of the Dice1.1 and Dice1.2 genes.
The Role of Dice1.1 and Dice1.2 in L. major Resistance.
The decreased susceptibility of L. majorinfected C.16D2/8 compared with control BALB/c indicates the existence of a disease response locus within the Dice1.2 congenic interval. Given the critical role of IL-4 regulation in L. major susceptibility (1), and given that Dice1.2 controls nIL-4 and Th2 cell bias, it is tempting to speculate that the same locus in the Dice1.2 congenic interval controls all three phenotypes. However, given that the nIL-4 and Th2 cell bias phenotypes of Dice1.1 are stronger than Dice1.2, how can we explain the inability of the Dice1.1 congenic strains to resist L. major infection? One possibility is that the magnitudes of the nIL-4 and Th2 cell bias phenotypes controlled by either Dice1.1 or Dice1.2 are insufficient to confer L. major resistance. Dice1.1 and Dice1.2 may act in parallel biochemical pathways, each with independent as well as common targets, L major susceptibility being a Dice1.2-specific target and Il4 a shared target. Alternatively, L. major resistance may require an additional gene cosegregating with Dice1.2. In this case, it should be possible to separate an L. major response locus (Lmr) from Dice1.2 itself. Such a locus would be predicted to behave like the recently described Lmr loci that use a Th1/Th2 cellindependent mechanism to control the differential responses to L. major of BALB/c and C57BL/6 (28). However, if a resistance locus in the Dice1.2 congenic interval operates in a Th1/Th2 cellindependent Lmr-like pathway, it would represent a novel member of this group because the known Lmr loci are located on chromosomes 9, 17, and X (28). Nevertheless, in support of this possibility is the similar abundance of Il4 mRNA recovered from draining popliteal lymph nodes 6 wk after L. major infection of resistant C.16D2/8 and susceptible BALB/c mice (unpublished data).
In summary, the genetic locus predicted by the Th2 cell biascontrolling Dice1 QTL is confirmed and resolved into two independent loci, Dice1.1 and Dice1.2. The additional ability of each locus to control Il4 expression from naive CD4 T cells, a known determinant of Th2 cell bias, suggests strongly that the proximal targets of both Dice1.1 and Dice1.2 occur in the naive T cell IL-4 pathway. In addition, Dice1.2 (or a tightly linked gene) controls the response to L. major infection, a paradigm for Th2 celldependent disease. The C.16D2 congenic panel will provide an opportunity to molecularly dissect the naive T cell IL-4 pathway and study the role of Th2 cell bias in the development of other Th2 celldependent processes such as worm expulsion, allergic asthma, and dermatitis.
![]() |
Acknowledgments |
---|
This work was supported by grants to M. Bix from the University of Washington Royalty Research Fund, the Marian Smith Foundation, the Burroughs Welcome Foundation, the Cancer Research Institute, and the National Institutes of Health (grant no. AI48636).
The authors have no conflicting financial interests.
Submitted: 19 February 2004
Accepted: 9 November 2004
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|